A Single Arm, Prospective, Open Label, Multi Center, Phase Ib Study to Evaluate the Safety, Tolerability and Initial Efficacy of a Single Intra-tumoral Injection of IntraGel's Polymer-based Cisplatin-loaded Gel (TumoCure) in Subjects With Progressive or Radio-resistant Primary Head and Neck Tumor

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 15, 2023

Primary Completion Date

May 15, 2025

Study Completion Date

July 1, 2025

Conditions

Head and Neck Cancer

Interventions

COMBINATION_PRODUCT

TumoCure

TumoCure is a polymer-based gel, loaded with Cisplatin in a dose of 100mg (10% w/w), injected to head and neck tumors locally in a single injection.

Trial Locations (1)

RECRUITING

Hadassah Medical Center, Jerusalem